Small clinical trials in liposarcoma andprostate cancer, which exhibit PPARγexpression, have also been promising in these malignancies,which exhibit PPARγ expression[60, 61].Recent in vitro evaluations in thyroid cancer cell lines have hinted at a possiblerole for PPARγ agonist therapy inredifferentiating neoplastic tissue, potentially enhancing the response tocurrently available therapies [62–67]. Here, PPARG is linked to thyroid gland carcinoma.